The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | TILs: Precision medicine in NSCLC
James Spicer, FCRP, PhD, MRCP, MBBS, King’s College London, London, UK, outlines the discussion around tumor infiltrating lymphocytes (TILs) at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 as a novel precision therapy to treat NSCLC. Many TIL therapies are presently in trials, and Prof. Spicer specifically mentions the CHIRON study (NCT04032847) which is focused on advanced NSCLC. This trial selects TILs post-amplification that specifically target the neoantigens arising from genomic mutations in a given patient’s tumor. This interview took place at the BTOG Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
